September 29, 2025

Uncategorized

New Releases from NCBI BookshelfSemaglutide (Wegovy): Indication: As an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of:: Reimbursement Recommendation [Internet].​Semaglutide (Wegovy): Indication: As an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of:: Reimbursement Recommendation [Internet].

Canada’s Drug Agency (CDA-AMC) recommends that Wegovy be reimbursed by public drug plans for chronic weight management if certain conditions

Uncategorized

New Releases from NCBI BookshelfCipaglucosidase Alfa (Pombiliti) With Miglustat (Opfolda): Indication: Cipaglucosidase alfa is indicated in combination with the enzyme stabilizer Opfolda (65 mg miglustat capsule) for the treatment of adult patients with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency) weighing ≥ 40 kg. Miglustat is an enzyme stabilizer indicated in combination with Pombiliti (cipaglucosidase alfa) for the treatment of adult patients with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency) weighing ≥ 40 kg. Cipaglucosidase alfa must be used in combination with 65 mg miglustat capsules: Reimbursement Recommendation [Internet].​Cipaglucosidase Alfa (Pombiliti) With Miglustat (Opfolda): Indication: Cipaglucosidase alfa is indicated in combination with the enzyme stabilizer Opfolda (65 mg miglustat capsule) for the treatment of adult patients with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency) weighing ≥ 40 kg. Miglustat is an enzyme stabilizer indicated in combination with Pombiliti (cipaglucosidase alfa) for the treatment of adult patients with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency) weighing ≥ 40 kg. Cipaglucosidase alfa must be used in combination with 65 mg miglustat capsules: Reimbursement Recommendation [Internet].

Canada’s Drug Agency (CDA-AMC) recommends that Pombiliti with Opfolda be reimbursed by public drug plans for the treatment of adult

Uncategorized

New Releases from NCBI BookshelfRelugolix-Estradiol–Norethindrone Acetate (Myfembree): Indication: Management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women: Reimbursement Recommendation [Internet].​Relugolix-Estradiol–Norethindrone Acetate (Myfembree): Indication: Management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women: Reimbursement Recommendation [Internet].

Canada’s Drug Agency (CDA-AMC) recommends that Myfembree should be reimbursed by public drug plans for the treatment of heavy menstrual

Scroll to Top